Finance

Lists
Q2 2027 earnings • released • EPS beat +110.57% • Revenue beat +11.00%
See results
PPLPHARMA:NSE
Piramal Pharma Ltd (Mumbai)
₹237.77
+3.03%
(+6.99) 1D
Oct 30, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for PPLPHARMA...
Open
₹229.95
High
₹240.00
Low
₹225.82
Mkt. cap
315.70B
Avg. vol.
7.22M
Volume
26.86M
52-wk high
₹240.00
52-wk low
₹132.30
EPS
-₹1.58
No. of employees
7K
Open
₹229.95
High
₹240.00
Low
₹225.82
Mkt. cap
315.70B
Avg. vol.
7.22M
Volume
26.86M
52-wk high
₹240.00
52-wk low
₹132.30
EPS
-₹1.58
No. of employees
7K
News stories
From web sources and news partners
About Piramal Pharma Ltd (Mumbai)
CEOPeter DeYoung
Employees7.12K
Founded2020
Headquarters-
SectorPharmaceutical industry
Last report
Oct 28, 2026
Fiscal period
Q2 2027
₹0.04 / -₹0.38
+110.57%beat
Revenue / Est. (INR)
26.17B / 23.58B
+11.00%beat
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
21.40B
27.52B
22.70B
26.17B
Cost of goods sold
7.86B
13.95B
8.52B
9.06B
Cost of revenue
7.86B
13.95B
8.52B
9.06B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.00B
8.19B
6.76B
7.14B
Operating expense
13.71B
11.09B
14.46B
15.95B
Total operating expenses
21.57B
25.04B
22.98B
25.01B
Operating income
-170.10M
2.47B
-283.50M
1.16B
Other non operating income
432.40M
-977.90M
894.10M
359.30M
EBT including unusual items
-938.60M
430.00M
-74.60M
816.30M
EBT excluding unusual items
-527.50M
1.40B
-74.60M
816.30M
Income tax expense
423.30M
518.30M
619.30M
766.00M
Effective tax rate
-45.10%
120.53%
-830.16%
93.84%
Other operating expenses
5.58B
723.30M
5.47B
6.48B
Net income
-1.36B
-88.30M
-693.90M
55.80M
Net profit margin
-6.36%
-0.32%
-3.06%
0.21%
Earnings per share
-0.72
1.32
-0.52
0.04
Interest and investment income
-
70.70M
-
-
Interest expense
-892.40M
-805.40M
-880.80M
-876.30M
Net interest expenses
-892.40M
-734.70M
-880.80M
-876.30M
Depreciation and amortization charges
2.13B
2.18B
2.24B
2.33B
EBITDA
1.68B
4.32B
1.57B
3.29B
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps